Advanced Enzyme Technologies Profile
Key Indicators
- Authorised Capital ₹ 35.00 Cr
- Paid Up Capital ₹ 22.36 Cr
- Company Age 35 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 50.00 Cr
- Satisfied Charges ₹ 198.50 Cr
- Revenue Growth 14.00%
- Profit Growth 1.86%
- Ebitda 3.08%
- Net Worth 9.36%
- Total Assets 8.72%
About Advanced Enzyme Technologies
Advanced Enzyme Technologies Limited (AETL) is a leading Public Limited Indian Non-Government Company incorporated in India on 15 March 1989 and has a history of 35 years and 11 months. Its registered office is in Thane, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 540025 and on the National Stock Exchange(NSE) under ADVENZYMES.
The Corporate was formerly known as Advanced Biochemicals Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 35.00 Cr and a paid-up capital of Rs 22.36 Cr.
The company currently has active open charges totaling ₹50.00 Cr. The company has closed loans amounting to ₹198.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Advanced Enzyme Technologies Limited India are Beni Rauka as CFO and Sanjay Basantani as Company Secretary. Nitin Deshmukh, Mukund Kabra, Kedar Desai, and Seven other members serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24200MH1989PLC051018
- Company No.
051018
- Stock Symbol
BSE : 540025 NSE : ADVENZYMES
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Mar 1989
- Date of AGM
12 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
What products or services does Advanced Enzyme Technologies Limited offer?
Advanced Enzyme Technologies Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Dietary Supplements.
Who are the key members and board of directors at Advanced Enzyme Technologies?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Beni Rauka  | CFO | 26-May-2015 | Current |
| Sanjay Basantani | Company Secretary | 14-Feb-2017 | Current |
Board Members (10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vasant Rathi  | Director | 05-Mar-1993 | Current |
| Rajshree Patel | Director | 12-Jun-2020 | Current |
| Pramod Kasat | Director | 14-Dec-2016 | Current |
| Nitin Deshmukh | Director | 01-Jul-2022 | Current |
| Mukund Kabra | Whole-Time Director | 04-Sep-1999 | Current |
| Kedar Desai | Director | 27-Aug-2010 | Current |
Financial Performance of Advanced Enzyme Technologies.
Advanced Enzyme Technologies Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14% increase. The company also saw a slight improvement in profitability, with a 1.86% increase in profit. The company's net worth moved up by a moderate rise of 9.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Advanced Enzyme Technologies?
In 2020, Advanced Enzyme Technologies had a promoter holding of 57.88% and a public holding of 42.13%. The company had 3 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tipco Industries Private LimitedKedar Desai is a mutual person
Samta Mines And Minerals LimitedNitin Deshmukh is a mutual person
Safepack Industries LimitedPramod Kasat is a mutual person
Innvolution Healthcare Private LimitedSunny Sharma is a mutual person
Innovation Imaging Technologies Private LimitedSunny Sharma is a mutual person
Marksans Pharma LimitedSunny Sharma is a mutual person
Charges (Loans)
₹50.00 Cr
₹198.50 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 15.00 Cr
- Citi Bank N.A. : 15.00 Cr
- Others : 10.00 Cr
- Axis Bank Limited : 5.00 Cr
- Dbs Bank Ltd. : 5.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jun 2022 | Axis Bank Limited | ₹5.00 Cr | Open |
| 10 Feb 2022 | Others | ₹10.00 Cr | Open |
| 11 Jun 2013 | Dbs Bank Ltd. | ₹5.00 Cr | Open |
| 28 Aug 2006 | Hdfc Bank Limited | ₹15.00 Cr | Open |
| 22 Jun 2005 | Citi Bank N.A. | ₹15.00 Cr | Open |
How Many Employees Work at Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a workforce of 462 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Advanced Enzyme Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Advanced Enzyme Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
